Royal Philips and Exor have updated their long-term relationship agreement, allowing Exor to increase its stake in the health technology company to 22%, up from a previous cap of 20%. Further increases would require approval from Royal Philips' supervisory board. Governance arrangements remain unchanged, including Exor's right to nominate one supervisory board member. Exor initially acquired a 15% shareholding in August 2023 to support Philips' long-term value creation plans. Royal Philips generated approximately 18 billion euros in sales in 2025.
Exor N.V.Exor can increase its stake to 22%, a positive capital move for Exor.
Koninklijke Philips NVPhilips updates agreement allowing Exor to increase stake, but governance unchanged; impact on Philips is neutral to slightly positive.
